
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. is positioned positively due to the strong momentum of its lead product, Auvelity, driven by its novel mechanism of action, rapid onset, and efficacy in treating major depressive disorder (MDD), further bolstered by anticipated improvements in payor coverage. The company's confidence regarding the upcoming sNDA submission of AXS-05 for Alzheimer's disease-associated agitation is supported by favorable pre-NDA feedback from the FDA, reflecting strong clinical trial results demonstrating statistically significant improvements across multiple studies. Additionally, the anticipated launch of SYMBRAVO, which shows rapid and sustained relief of migraine pain, complements Axsome's promising pipeline of therapies designed to address CNS disorders with currently limited treatment options.
Bears say
Axsome Therapeutics faces multiple significant risks that contribute to a negative outlook on its stock, including potential lower market access for its product AUVELITY and setbacks in clinical trials, particularly for its leading candidate AXS-05 in treatment-resistant depression and smoking cessation. Additionally, the company may struggle to secure timely approvals for its pipeline products AXS-12 and AXS-14, which could hinder growth opportunities. There is also a concern regarding lower-than-projected commercial success due to heightened competition, as well as risks associated with long-term shareholder dilution.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares